Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Adenios
AddedFeb 18, 2024
UpdatedJun 18, 2026
Adenios

Adenios

Pre-Seed

Adenios: Innovating drug delivery tech for central nervous system disorder treatments.

HQ
Ithaca, NY, US
Founded
2009
Overview
Compare
Fundraising
Employees

Adenios focuses on developing, manufacturing, and distributing drugs that control the blood/brain barrier. Their mission is to innovate drug delivery technologies for treating central nervous system disorders such as Alzheimer's, Parkinson's, brain cancer, and multiple sclerosis.

Adenios has made significant strides in CNS disorder treatments, contributing to advancements in medical research and patient care. Their impact is evident in the improved management of complex neurological conditions, positioning them as a key player in the biotech industry.

Adenios - Similar Companies

Caden Biosciences logo

Caden Biosciences

Kurve Therapeutics logo

Kurve Therapeutics

kurvetx.com

Adrx logo

Adrx

adrxpharma.com

Reservoir Neuroscience logo

Reservoir Neuroscience

reservoirneuro.com

Mithridion logo

Mithridion

Zenomics logo

Zenomics

CuraSen Therapeutics logo

CuraSen Therapeutics

curasen.com

Ophidion logo

Ophidion

Aliada Therapeutics logo

Aliada Therapeutics

aliadatx.com

Alcyone Lifesciences logo

Alcyone Lifesciences

MapLight Therapeutics logo

MapLight Therapeutics

Axonis Therapeutics logo

Axonis Therapeutics

Aptinyx logo

Aptinyx

aptinyx.com

Camino Pharma logo

Camino Pharma

caminopharma.com

NeurOp logo

NeurOp

Adenios - Quick Facts

Who are Adenios' competitors?

Companies similar to Adenios include Caden Biosciences, Kurve Therapeutics, Adrx and Reservoir Neuroscience.

When was Adenios founded?

Adenios was founded in 2009.

Where is Adenios' headquarters located?

Adenios' headquarters is located in Ithaca, NY, US.

When was Adenios' last funding round?

Adenios' most recent funding round was for $810k (USD) in February 2010.

How much has Adenios raised to-date?

As of Feb 16, 2010, Adenios has raised a total of $810k (USD).

How many employees does Adenios have?

Adenios has 6 employees as of Feb 5, 2024.

Adenios - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Drug Delivery
Tags
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 16 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 325000Chemical Manufacturing
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 325410Pharmaceutical and Medicine Manufacturing
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 2830Drugs
  • 8730Research, Development, And Testing Services
  • 2834Pharmaceutical Preparations
  • 8731Commercial Physical and Biological Research